Lenk Robert P

Average Profitability
<0.0001%
Insider Buys Quantity
11
Insider Buys Sum
$68,175.39
Insider Sells Quantity
1
Insider Sells Sum
$472.05

Insider Activity of Lenk Robert P

According to the SEC Form 4 filings, Lenk Robert P, being in a position of

  1. director at Plus Therapeutics, Inc.,
    оver the last 12 months, has bought 28761 share for $47,700, and sold 0 shares,
    over all time since 2020-08-25, has bought 38761 share for $68,175, and sold 1500 shares for $472.

The largest purchase of all time was on 2021-09-13 and amounted to 7000 shares of Plus Therapeutics, Inc. for $13,011.

The largest sale of all time was on 2022-12-30 and amounted to 1500 shares of Plus Therapeutics, Inc. for $472.

Biography of Lenk Robert P

No biography is available at this moment.

2024-05-08PurchasePlus Therapeutics, Inc.
PSTV
director
4,167
0.0876%
$2.04$8,501-23.79%
2023-11-16PurchasePlus Therapeutics, Inc.
PSTV
director
1,000
0.02%
$1.95$1,950-15.07%
2023-11-15PurchasePlus Therapeutics, Inc.
PSTV
director
1,000
0.0206%
$1.77$1,770-0.53%
2023-11-13PurchasePlus Therapeutics, Inc.
PSTV
director
4,000
0.086%
$1.43$5,720+26.53%
2023-11-10PurchasePlus Therapeutics, Inc.
PSTV
director
2,000
0.0452%
$1.45$2,900+32.38%
2023-11-09PurchasePlus Therapeutics, Inc.
PSTV
director
4,199
0.0971%
$1.59$6,676+24.33%
2023-11-08PurchasePlus Therapeutics, Inc.
PSTV
director
5,000
0.1147%
$1.65$8,250+16.35%
2023-11-07PurchasePlus Therapeutics, Inc.
PSTV
director
6,000
0.1303%
$1.64$9,840+12.12%
2023-11-06PurchasePlus Therapeutics, Inc.
PSTV
director
1,395
0.0286%
$1.50$2,093+14.91%
2022-12-30SalePlus Therapeutics, Inc.
PSTV
director
1,500
0.0004%
$0.31$472-41.88%
2021-09-13PurchasePlus Therapeutics, Inc.
PSTV
director
7,000
0.0036%
$1.86$13,011-45.9%
2020-08-25PurchasePlus Therapeutics, Inc.
PSTV
director
3,000
0.0046%
$2.49$7,465-3.47%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.